Wealth Alliance Advisory Group’s Moderna MRNA Stock Holding History

Wealth Alliance Advisory Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$390K	Buy	+2,025	New	+$218K	0.05%	137

Other funds holding MRNA

Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return

Beau Ventures, LLc Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Legal Advantage Investments Los Altos Hills, California $468M AUM 7.83% 1-Year Est. Return

Patton Fund Management Dallas, Texas $389M AUM 65.14% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Gallagher Capital Advisors Argyle, Texas $187M AUM 21.63% 1-Year Est. Return

Nicollet Investment Management Minneapolis, Minnesota $336M AUM 22.24% 1-Year Est. Return

Blue Sky Capital Consultants Group Poway, California $239M AUM 14.34% 1-Year Est. Return

Wealth Enhancement Advisory Services

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Wealth Alliance Advisory Group's MRNA Position: Q3 2026 in Review

Wealth Alliance Advisory Group opened a new position in Moderna (MRNA) in Q3 2026: 2,025 shares worth $390K. The stake represents 0.05% of the portfolio and ranks #137 among its holdings.

69 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

Wealth Alliance Advisory Group held 2,025 shares of Moderna worth $390K as of Q3 2026.
Moderna was a new Wealth Alliance Advisory Group position in Q3 2026.
Moderna made up 0.05% of Wealth Alliance Advisory Group's portfolio in Q3 2026, its #137 holding.
69 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Wealth Alliance Advisory Group's 13F filing for Q3 2026, filed 14 Oct 2026.